Predictors of Early Myocardial Infarction
In multivariable analysis, strong predictors for MI ≤45 years were hypertension or diabetes, active smoking, family history, BMI ≥30 kg/m.
Myocardial Infarction
Predictors of Upper GI Bleeding Identified After Acute MI
UGIB after MI linked to increased risk for all-cause mortality and stroke, but not recurrent myocardial infarction; predictors of UGIB include age and smoking status.
Low-Dose Colchicine Reduced Ischemic CV Event Risk Irrespective of Prior MI
The anti-inflammatory benefits of colchicine were consistently observed in this study, regardless of specific history and timing of prior ACS.
C-peptide Independently Associated With Subclinical Myocardial Injury
C-peptide level may be independently associated with both cardiac injury score (CIIS) and subclinical myocardial injury.
Biomarkers Distinguish Between Subtypes of Myocardial Infarction and Injury
Researchers assessed the value of a biomarker model in distinguishing subtypes of myocardial infarction and injury.
Neprilsyin Plus RAS Inhibition Did Not Significantly Reverse Post-MI LV Remodeling
Neprilysin inhibition was not found to have a significant effect on late LV remodeling after myocardial infarction.
What Is the Most Appropriate Antiplatelet De-Escalation Strategy in ACS?
DAPT de-escalation was ranked as the most effective strategy for preventing all-cause and cardiovascular death in patients with acute coronary syndrome.
Mortality Rates From Acute Myocardial Infarction Similar Among Patients With PsA and General Population
The objective of the study was to evaluate the trends for hospitalizations and inpatient mortality from acute myocardial infarction among patients with psoriatic arthritis.
Intensive Prevention Program Decreases Long-Term Risks After MI
This study evaluated the effects of a 12-month intensive prevention program based on regular contacts between nonphysician “prevention assistants” and patients who had had an MI.
Dual-Pathway Inhibition in Cardiovascular Disease: Efficacy and Safety
The study authors conducted a systematic review and meta-analysis to assess the overall efficacy and safety of low-dose direct oral anticoagulants vs placebo on a background of antiplatelet therapy.
- Loading...
Loading...
Next post in Thrombosis
Loading... 
Loading...